IP Library Granted Patent US 7,462,448
Granted Patent B2
US 7,462,448 · App. 10/633,141 · Granted Dec 9, 2008

Species specific DNA detection

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,462,448
App. No.
10/633,141
Granted
Dec 9, 2008
Kind
B2
Abstract

The present invention relates to methods and compositions for the identification of species-specific material in pharmaceutical products. In particular, the present invention relates to methods for the identification of species-specific DNA in a population of a different species or following contact (e.g., growth) with cells of a different species.

Claims (35)

1. A method for detecting species-specific nucleic acid, comprising:

a) providing

i) a nucleic acid sample from a culture of cells of a first species, wherein said culture has had previous exposure to a second culture of cells from a second species or a cell product derived from said cells from a second species;

ii) first nucleic acid probes specific for nucleic acid from said second species; and

(iii) second nucleic acid probes specific for said first species;

b) exposing said sample to said first nucleic acid probes under conditions such that said first nucleic acid probes hybridize to nucleic acid from said second species and do not hybridize to nucleic acid from said first species to detect nucleic acid from said second species; and

c) exposing said sample to said second nucleic acid probes, wherein said second nucleic acid probes are selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4, under conditions such that said second nucleic acid probes hybridize to nucleic acid from said first species and do not hybridize to nucleic acid from said second species to detect nucleic acid from said first species.

2. The method of claim 1 , wherein said first nucleic acid probes are specific for a repetitive element of nucleic acid in the genome of said second species.

3. The method of claim 2 , wherein at least 20 copies of said repetitive element are present in the genome of said second species.

4. The method of claim 1 , wherein said cells from a second species are selected from the group consisting of rat cells, mouse cells, and porcine cells.

5. The method of claim 1 , wherein said exposing of b) and/or c) comprises PCR.

6. The method of claim 5 , wherein said first nucleic acid probes and/or said second nucleic acid probes are PCR primers.

7. The method of claim 1 , wherein said first nucleic acid probes and said second nucleic acid probes are PCR primers, and wherein said exposing of b) and c) comprises PCR, and wherein said PCR is a multiplex PCR reaction.

8. The method of claim 1 , wherein said first nucleic acid probes are selected from the group consisting of SEQ ID NOs: 1, 2, and 5-26.

9. The method of claim 1 , wherein said culture of cells of a first species is a cultured human skin tissue.

10. The method of claim 9 , wherein said cultured human skin tissue comprises keratinocytes selected from the group consisting of primary keratinocytes and immortalized keratinocytes.

11. The method of claim 10 , wherein said immortalized keratinocytes are NIKS cells.

12. The method of claim 1 , wherein said culture of cells of a first species comprises stem cells.

13. The method of claim 1 , wherein said cells from a second species comprise feeder cells.

14. The method of claim 13 , wherein said feeder cells are mouse fibroblast cells.

15. A method for detecting species-specific nucleic acid, comprising:

a) providing

i) a nucleic acid sample from a culture of cells from a first species, wherein said culture has had previous exposure to a feeder layer from a second species;

ii) first nucleic acid probes specific for nucleic acid derived from said feeder layer from said second species, wherein said first nucleic acid probes are selected from the group consisting of SEQ ID NOs: 1, 2, and 5-26; and

iii) second nucleic acid probes specific for said first species selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4;

b) exposing said sample to said first nucleic acid probes under conditions such that said first nucleic acid probes hybridize to nucleic acid derived from said feeder layer and do not hybridize to nucleic acid from said first species to detect nucleic acid from said second species; and

c) exposing said sample to said second nucleic acid probes under conditions such that said second nucleic acid probes hybridize to nucleic acid from said first species and do not hybridize to nucleic acid from said second species to detect nucleic acid from said first species.

16. The method of claim 15 , wherein said first nucleic acid probes are specific for a repetitive element of nucleic acid in the genome of said second species.

17. The method of claim 16 , wherein at least 20 copies of said repetitive element are present in the genome of said second species.

18. The method of claim 15 , wherein said feeder layer is a mouse cell feeder layer.

19. The method of claim 15 , wherein said exposing of b) and/or c) comprises PCR.

20. The method of claim 19 , wherein said first nucleic acid probes and/or said second nucleic acid probes are PCR primers.

21. The method of claim 15 , wherein said first nucleic acid probes and said second nucleic acid probes are PCR primers, and wherein said exposing of b) and c) comprises PCR, and wherein said PCR is a multiplex PCR reaction.

22. The method of claim 15 , wherein said culture of cells from a first species is a cultured human skin tissue.

23. The method of claim 22 , wherein said cultured human skin tissue comprises NIKS cells.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 040059, FRAME 0222 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0083 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 16, 2016
From: STRATATECH CORPORATION
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 040059/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2004
From: ALLEN-HOFFMANN, LYNN; CENTANNI, JOHN M.
To: STRATATECH CORPORATION
Reel/Frame 015211/0277 →